Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederinvestors.amgen.com
Amgen Inc. News Releases
Get the latest updates from Amgen Inc. News Releases directly as they happen.
Follow now 189 followers
Latest posts
Last updated 13 days ago
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
13 days ago
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
13 days ago
THOUSAND OAKS, Calif. , Nov. 24, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will...
FDA GRANTS FULL APPROVAL TO AMGEN'S IMDELLTRA® IN EXTENSIVE STAGE SMALL CELL LUNG CANCER
18 days ago
Global Confirmatory Phase 3 DeLLphi-304 Trial Showed IMDELLTRA Reduced Risk of Death...
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
29 days ago
Study Also Shows 36% Reduction in Risk of Heart Attack Repatha is...
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
about 1 month ago
THOUSAND OAKS, Calif. , Nov. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
about 1 month ago
THOUSAND OAKS, Calif. , Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
about 1 month ago
Repatha VESALIUS-CV Trial Met Dual Primary Endpoints Demonstrating Reduction in CV Events...
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
about 1 month ago
THOUSAND OAKS, Calif. , Oct. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today...
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
about 2 months ago
Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven...
AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.
2 months ago
Eligible Patients Can Access Repatha at Nearly 60% Discount From the List...
/C O R R E C T I O N -- Amgen/
2 months ago
In the news release, AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT...
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
2 months ago
Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments...